{"id":47671,"date":"2022-08-25T17:01:46","date_gmt":"2022-08-25T15:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/"},"modified":"2022-08-25T17:01:46","modified_gmt":"2022-08-25T15:01:46","slug":"ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/","title":{"rendered":"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies"},"content":{"rendered":"
\n

\nFreely available report shows potential to perform up to 50 times more tests <\/i>of genetically engineered cells in solid tumor samples<\/i>\n<\/p>\n

PISCATAWAY, N.J.–(BUSINESS WIRE)–#EMBS<\/a>–IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS)<\/a>, today announced the publication of a report that demonstrates how a new 3D screening tool can help accelerate the development of cancer treatments through a new testing method that increases the number of tests on solid tumor samples by up to 50 times and potentially facilitates larger-scale testing of innovative immunotherapies. The report, derived from research led by the University of Strathclyde in Glasgow, Scotland, has been published in IEEE Open Journal of Engineering<\/i> in Medicine and Biology<\/i><\/a>, and is freely available for open access and full-text viewing by all readers around the world.\n<\/p>\n

<\/a><\/p>\n

\nThe report, \u201cAssessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy<\/a>,\u201d which also is available in the IEEE Xplore<\/i>\u00ae<\/sup> digital library, details a more-than-two-year study of screening 3D tumor models with a miniaturized technology platform to evaluate the toxicity of genetically engineered Chimeric Antigen Receptor T (CAR-T) cells used in immunotherapies. Researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow also contributed to the study.\n<\/p>\n

\n\u201cOur study illustrates the promise of our microfluidic technology platform to accelerate the development of leading-edge therapies by enabling 20 to 50 times more experiments to be performed on a solid tumor sample,\u201d said Dr. Michele Zagnoni, a reader in Strathclyde\u2019s Department of Electronic and Electrical Engineering, who led the study along with doctoral student Karla Paterson. \u201cCAR-T cell development is typically very expensive, and our research indicates that the miniaturized 3D modeling we employed, which is not yet widely established in the pharma industry, could facilitate significantly more effective and cost-efficient developmental immunotherapies. We look forward to seeing its life-saving impact in preclinical drug testing and, ultimately, precision medicine in the clinic.\u201d\n<\/p>\n

\nSolid tumors are complex environments including both cancerous and noncancerous cells. The IEEE Open Journal of Engineering in Medicine and Biology<\/i> report details how the microfluidic technology in the study effectively enabled visualization and quantification of the ability of CAR-T cells to rapidly kill the cancer cells without significantly harming the other cells in a tumor sample. The research also revealed that the efficacy of chemotherapies can be improved when combined with CAR-T cell treatment. The deep look into how CAR-T cells do their work was enabled by the 3D models used in the Strathclyde study, which more closely reproduce the complexity of actual tumor microenvironments in the human body than is possible via legacy 2D modeling.\n<\/p>\n

\n\u201cThis report is of equally keen interest to engineers and scientists in medicine and biology. We look forward to further spurring the conversation with more papers of this type and in this topic area,\u201d said Paolo Bonato, editor-in-chief of IEEE Open Journal of Engineering in Medicine and Biology<\/i>. \u201cIEEE EMBS has a valuable transdisciplinary dimension with substantial interaction among expertise across diverse technology areas, and, so, we publish papers both where the main emphasis is on methodology and technology and where the main emphasis is on science. Bridging these two worlds with an open-access journal is crucial to advancing innovative research into concrete, real-world benefit to society.\u201d\n<\/p>\n

\nAbout IEEE<\/b>\n<\/p>\n

\nIEEE is the world\u2019s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more<\/a>.\n<\/p>\n

\nAbout the IEEE Engineering in Medicine and Biology Society<\/b>\n<\/p>\n

\nThe IEEE Engineering in Medicine and Biology Society (EMBS) is the world’s largest international society of Biomedical Engineers. With more than 9,500 members residing in some 97 countries around the world, it’s a true global connection, providing access to the most fascinating people, practices, information, ideas, opinion and fellowship from one of science’s fastest growing fields: biomedical engineering. From formalized mathematical theory through experimental science, from technological development to practical clinical applications, IEEE EMBS members support scientific, technological, and educational activities as they apply to the concepts and methods of the physical and engineering sciences in biology and medicine. By working together, we can transform and revolutionize the future of medicine and healthcare. For more information about the IEEE EMBS, please visit www.embs.org<\/a>.\n<\/p>\n

\nAbout the IEEE Open Journal of Engineering in Medicine and Biology<\/i><\/b>\n<\/p>\n

\nThe IEEE Open Journal of Engineering in Medicine and Biology<\/i><\/a> covers the development and application of engineering concepts and methods to biology, medicine and health sciences to provide effective solutions to biological, medical and healthcare problems.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMonika Stickel
\n
+1 732 562 6027
\n
m.stickel@ieee.org<\/a>\n<\/p>\n

\nFrancine Tardo
\n
+1 732 465 5865
\n
f.tardo@ieee.org<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Freely available report shows potential to perform up to 50 times more tests of genetically engineered cells in solid tumor samples PISCATAWAY, N.J.–(BUSINESS WIRE)–#EMBS–IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS), today announced the publication of a report that demonstrates … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47671","6":"format-standard","7":"category-industry"},"yoast_head":"\nIEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Freely available report shows potential to perform up to 50 times more tests of genetically engineered cells in solid tumor samples PISCATAWAY, N.J.–(BUSINESS WIRE)–#EMBS–IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS), today announced the publication of a report that demonstrates ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T15:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220825005482\/en\/1553584\/21\/IEEE_EMBS_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies\",\"datePublished\":\"2022-08-25T15:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/\"},\"wordCount\":834,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005482\\\/en\\\/1553584\\\/21\\\/IEEE_EMBS_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/\",\"name\":\"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005482\\\/en\\\/1553584\\\/21\\\/IEEE_EMBS_Logo.jpg\",\"datePublished\":\"2022-08-25T15:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005482\\\/en\\\/1553584\\\/21\\\/IEEE_EMBS_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005482\\\/en\\\/1553584\\\/21\\\/IEEE_EMBS_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/","og_locale":"en_US","og_type":"article","og_title":"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies - Pharma Trend","og_description":"Freely available report shows potential to perform up to 50 times more tests of genetically engineered cells in solid tumor samples PISCATAWAY, N.J.–(BUSINESS WIRE)–#EMBS–IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS), today announced the publication of a report that demonstrates ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-25T15:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220825005482\/en\/1553584\/21\/IEEE_EMBS_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies","datePublished":"2022-08-25T15:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/"},"wordCount":834,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220825005482\/en\/1553584\/21\/IEEE_EMBS_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/","url":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/","name":"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220825005482\/en\/1553584\/21\/IEEE_EMBS_Logo.jpg","datePublished":"2022-08-25T15:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220825005482\/en\/1553584\/21\/IEEE_EMBS_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220825005482\/en\/1553584\/21\/IEEE_EMBS_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ieee-open-journal-of-engineering-in-medicine-and-biology-report-details-promise-of-new-3d-screening-tool-for-accelerating-leading-edge-cancer-immunotherapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47671"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47671\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}